Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | USP28 | Q96RU2 | 2/20 | 0.36 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | VSIR | Q9H7M9 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28300111 | 0.81 | GSR (0.50) | GSRSMN1; SMN2CD274PDCD1ALDH1A1 | |
| SCHEMBL2854317 | 0.80 | SMN1; SMN2 (0.46) | GSRSMN1; SMN2CD274PDCD1ALDH1A1 | |
| SCHEMBL22395226 | 0.76 | CYP1A2 (0.50) | GSRSMN1; SMN2CD274PDCD1ALDH1A1 | |
| SCHEMBL29912778 | 0.75 | USP28 (0.40) | GSRSMN1; SMN2CD274ALDH1A1USP28 | |
| SCHEMBL4574283 | 0.75 | USP28 (0.40) | GSRSMN1; SMN2CD274ALDH1A1USP28 | |
| SCHEMBL15587609 | 0.73 | GSR (0.47) | GSRSMN1; SMN2CD274PDCD1MEN1 | |
| SCHEMBL23803596 | 0.73 | THRB (0.42) | — | |
| SCHEMBL29220938 | 0.72 | GSR (0.50) | GSRSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL29037434 | 0.72 | GSR (0.55) | GSRSMN1; SMN2CD274PDCD1ALDH1A1 | |
| SCHEMBL4599034 | 0.72 | CHRM2 (0.64) | SMN1; SMN2CD274PDCD1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618960-B2 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| EP-1953154-A1 | MORPHOLINE TYPE CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117798-A1 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117798-A1 | Morpholine type cinnamide compound | MLX, XDH, NOX4 | GSR 2103/4885SMN1; SMN2 642/4885CD274 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.